- Conditions
- Disorder Related to Renal Transplantation
- Interventions
- Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 67
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
- Interventions
- Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 69 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hematologic Neoplasms
- Interventions
- donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
- Interventions
- Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
- Conditions
- DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
- Interventions
- Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
- Biological · Other · Procedure + 1 more
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Kidney Transplant Rejection, Immunosuppression
- Interventions
- TruGraf, Standard of Care
- Diagnostic Test · Other
- Lead sponsor
- Transplant Genomics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- umbilical cord blood transplantation, fludarabine phosphate, cyclophosphamide, ex vivo-expanded cord blood progenitor cell infusion, total-body irradiation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Nohla Therapeutics, Inc.
- Industry
- Eligibility
- 6 Months to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
- Interventions
- Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • Bethesda, Maryland
- Conditions
- Liver Cirrhosis, Liver Transplant Disorder
- Interventions
- Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lysosomal Storage Disease, Peroxisomal Disorder
- Interventions
- Campath-1H, Clofarabine, Melphalan, Total Body Irradiation with Marrow Boosting, Hematopoietic stem cell transplantation, Cyclosporine A, Mycophenolate mofetil
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
- Interventions
- Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Interventions
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hematologic Malignancies, Graft vs Host Disease
- Interventions
- reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), vorinostat
- Procedure · Drug
- Lead sponsor
- Pavan Reddy, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
- Interventions
- Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End-stage Renal Failure, Kidney Graft Rejection
- Interventions
- Blood drawing for immune monitoring and questionnaires
- Other
- Lead sponsor
- University of Regensburg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- San Francisco, California • Boston, Massachusetts
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Uveitis
- Interventions
- Mycophenolate mofetil, Methotrexate, Prednisone
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Portland, Oregon
- Conditions
- Kidney Transplant
- Interventions
- Sirolimus, Belatacept, Mycophenolate Mofetil, Tacrolimus (Group1), Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Myelodysplastic Syndrome, Leukemia
- Interventions
- Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF
- Procedure · Drug · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
- Interventions
- Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
- Drug · Radiation · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Interventions
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota